Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities

Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge f...

Descripción completa

Detalles Bibliográficos
Autores principales: Porru, Manuela, Pompili, Luca, Caruso, Carla, Biroccio, Annamaria, Leonetti, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850913/
https://www.ncbi.nlm.nih.gov/pubmed/29534749
http://dx.doi.org/10.1186/s13046-018-0719-1
_version_ 1783306307216867328
author Porru, Manuela
Pompili, Luca
Caruso, Carla
Biroccio, Annamaria
Leonetti, Carlo
author_facet Porru, Manuela
Pompili, Luca
Caruso, Carla
Biroccio, Annamaria
Leonetti, Carlo
author_sort Porru, Manuela
collection PubMed
description Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.
format Online
Article
Text
id pubmed-5850913
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58509132018-03-21 Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities Porru, Manuela Pompili, Luca Caruso, Carla Biroccio, Annamaria Leonetti, Carlo J Exp Clin Cancer Res Research Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group. BioMed Central 2018-03-13 /pmc/articles/PMC5850913/ /pubmed/29534749 http://dx.doi.org/10.1186/s13046-018-0719-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Porru, Manuela
Pompili, Luca
Caruso, Carla
Biroccio, Annamaria
Leonetti, Carlo
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
title Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
title_full Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
title_fullStr Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
title_full_unstemmed Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
title_short Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
title_sort targeting kras in metastatic colorectal cancer: current strategies and emerging opportunities
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850913/
https://www.ncbi.nlm.nih.gov/pubmed/29534749
http://dx.doi.org/10.1186/s13046-018-0719-1
work_keys_str_mv AT porrumanuela targetingkrasinmetastaticcolorectalcancercurrentstrategiesandemergingopportunities
AT pompililuca targetingkrasinmetastaticcolorectalcancercurrentstrategiesandemergingopportunities
AT carusocarla targetingkrasinmetastaticcolorectalcancercurrentstrategiesandemergingopportunities
AT biroccioannamaria targetingkrasinmetastaticcolorectalcancercurrentstrategiesandemergingopportunities
AT leonetticarlo targetingkrasinmetastaticcolorectalcancercurrentstrategiesandemergingopportunities

Ejemplares similares